A clinical briefing for providers on Metformin/Sitagliptin (Janumet) availability, prescribing considerations, alternatives, and patient access tools in 2026.
Metformin/Sitagliptin — marketed as Janumet, Janumet XR, and the authorized generics Zituvimet and Zituvimet XR — remains a widely prescribed combination therapy for type 2 diabetes. While no formal FDA shortage exists as of early 2026, many providers are hearing from patients who struggle to locate or afford this medication at their local pharmacies.
This briefing covers the current supply landscape, prescribing implications, cost and access challenges, and practical tools to help your patients maintain continuity of care.
Understanding the context helps frame today's availability challenges:
While the NDMA recalls did not directly affect Janumet, they created lasting supply chain disruptions and increased scrutiny of Metformin-containing products.
Most major payers — including UnitedHealthcare, Cigna, and many Blue Cross plans — require step therapy for DPP-4 inhibitor combinations. The typical protocol requires documented inadequate glycemic control on Metformin monotherapy before approving Janumet or equivalent products. Key considerations:
When writing prescriptions for Metformin/Sitagliptin, consider these approaches to maximize fill rates:
As of Q1 2026, here is the supply status across formulations:
Mail-order pharmacies generally maintain more reliable inventory of all formulations.
Cost remains the primary barrier to access for many patients:
For patients on Medicare or Medicaid, the authorized generic Zituvimet often provides the most favorable cost position. Refer patients to our savings guide for a comprehensive breakdown.
These tools can help streamline the prescription-to-fill process for your patients:
Medfinder helps patients locate pharmacies with current stock of specific medications. Direct patients to medfinder.com to check Metformin/Sitagliptin availability near them before they leave your office. This proactive step can prevent the frustration of arriving at a pharmacy only to learn the drug is out of stock.
When facing a PA denial:
Direct patients to these resources for additional support:
When Metformin/Sitagliptin is unavailable or not covered, consider these evidence-based alternatives:
For a patient-facing comparison of alternatives, see our alternatives guide.
Several developments may improve access in the coming months:
While Metformin/Sitagliptin is not in a formal shortage, the combination of limited generic competition, high cost, and payer restrictions creates meaningful access barriers for patients. Providers can help by writing flexible prescriptions, proactively addressing insurance hurdles, and directing patients to availability tools like Medfinder and cost-saving resources like the Merck Savings Card and patient assistance programs.
Continuity of diabetes therapy is critical. A few minutes of proactive planning during the office visit can prevent days of disrupted treatment for your patients.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
